Key Points
- CFO Troy Wichterman sold 588 shares at an average price of $20.74 for proceeds of $12,195.12, reducing his stake by 0.27% to 220,649 shares, according to an SEC Form 4 filing.
- Several other executives also made small open‑market sales at roughly the same price, which are modest versus their holdings but could generate near‑term bearish sentiment.
- BLFS is trading around $19.61—below its 50‑ and 200‑day moving averages—with institutional ownership near 93.2%; analysts hold a consensus "Moderate Buy" rating and a $32 price target.
BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby Mathew sold 529 shares of the company's stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $20.74, for a total value of $10,971.46. Following the completion of the sale, the executive vice president owned 392,937 shares of the company's stock, valued at $8,149,513.38. This represents a 0.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
BioLife Solutions Stock Performance
BioLife Solutions stock traded down $0.66 during midday trading on Friday, hitting $19.46. 191,494 shares of the company's stock were exchanged, compared to its average volume of 403,642. The company has a market cap of $939.92 million, a PE ratio of -176.89 and a beta of 1.90. BioLife Solutions, Inc. has a 12 month low of $19.10 and a 12 month high of $29.62. The firm has a 50-day moving average of $23.47 and a two-hundred day moving average of $25.10.
Wall Street Analyst Weigh In
Several research analysts have weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $32.00 target price on shares of BioLife Solutions in a research note on Monday, December 29th. Wall Street Zen raised BioLife Solutions from a "hold" rating to a "buy" rating in a report on Saturday, February 28th. Weiss Ratings restated a "sell (d-)" rating on shares of BioLife Solutions in a research note on Wednesday, January 21st. Zacks Research upgraded shares of BioLife Solutions from a "hold" rating to a "strong-buy" rating in a research report on Friday, January 23rd. Finally, Northland Securities set a $34.00 price target on shares of BioLife Solutions in a research note on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $32.00.
View Our Latest Stock Report on BLFS
More BioLife Solutions News
Here are the key news stories impacting BioLife Solutions this week:
- Positive Sentiment: Analyst/preview piece says BioLife completed a strategic refocus on core biopreservation media and vials, expects ~17–20% revenue growth in FY2026, positive GAAP net income and mid‑60s gross margins; cites PanTHERA acquisition and QKine partnership as drivers of higher ARPU and product launches late‑2026. BioLife Looks Strong For Fiscal Year 2026
- Positive Sentiment: Company presentation/press release reiterated growth and strategic refocus, supporting management’s turnaround narrative and guidance to investors. BioLife Solutions Highlights Growth and Strategic Refocus in Presentation
- Neutral Sentiment: Reported short‑interest metrics show zero shares / 0.0 days‑to‑cover — figures appear erroneous or non‑informative, so there’s no clear evidence of significant short pressure at present. MarketBeat BLFS
- Negative Sentiment: Several senior insiders (CFO, CMO, EVP, CTO and others) disclosed open‑market sales of modest blocks (hundreds of shares each at ≈$20.74). While amounts are small relative to their holdings, clustered executive selling can create near‑term investor concern and headline risk. Insider trading alert
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. Global Retirement Partners LLC acquired a new stake in BioLife Solutions in the fourth quarter worth $30,000. Kemnay Advisory Services Inc. bought a new position in shares of BioLife Solutions during the 4th quarter worth approximately $35,000. Hantz Financial Services Inc. boosted its position in BioLife Solutions by 54.1% in the third quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider's stock worth $48,000 after purchasing an additional 659 shares during the last quarter. Quarry LP raised its position in BioLife Solutions by 50.9% in the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider's stock worth $54,000 after acquiring an additional 713 shares during the period. Finally, Ameritas Investment Partners Inc. increased its stake in shares of BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider's stock worth $83,000 after purchasing an additional 441 shares during the last quarter. 93.24% of the stock is owned by institutional investors.
About BioLife Solutions
(
Get Free Report)
BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife's product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.
The company's flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
